Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer

Sabrina Rossi, Giovanna Finocchiaro, Vincenzo Di Noia, Maria Bonomi, Eleonora Cerchiaro, Fiorenza De Rose, Davide Franceschini, Pierina Navarria, Giovanni Luca Ceresoli, Giordano Domenico Beretta, Ettore D'Argento, Marta Scorsetti, Armando Santoro, Luca Toschi

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: The association of tyrosine kinase inhibitors (TKIs) and local radiotherapy in EGFR-mutated non-small-cell lung cancer patients experiencing disease progression under TKIs could be a valid an option. Patients & methods: We included 131 patients experiencing disease progression during first-line TKI. In group A, patients received TKI beyond progression and site(s) of progression were irradiated; in group B, patients remained on TKI alone beyond progression; and group C stopped TKI at first disease progression. Results: Median overall survival resulted longer in group A versus B and C (p < 0.0001). Group A had a trend toward a longer second progression-free survival (measured from the time of first progression until second progression) versus group B (p = 0.06). Conclusion: TKI beyond progression in association with local ablative treatment is a valid treatment option in oligoprogressive patients.

Original languageEnglish
Pages (from-to)3775-3782
Number of pages8
JournalFuture oncology (London, England)
Volume15
Issue number33
DOIs
Publication statusPublished - Nov 2019

Fingerprint Dive into the research topics of 'Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this